安罗替尼在中晚期肝癌介入术后的临床疗效观察

Clinical Efficacy of Antinib in Patients with Advanced Hepatocellular Carcinoma after Interventional Therapy

目的:分析应用安罗替尼在中晚期肝癌介入术后的临床疗效。方法:选取2014年1月-2016年1月笔者所在医院收治的60例中晚期肝癌介入术患者,按随机数字表法分为两组,每组30例。A组采用肝癌介入术治疗,B组采用介入术联合安罗替尼治疗;比较观察两组治疗前后的肝功能指标、不良反应发生情况、肿瘤控制率及治疗总有效率。结果:两组治疗后AST、ALT水平比较差异无统计学意义(P>0.05);B组的肿瘤控制率及治疗总有效率高于A组(P<0.05);B组平均生存周期长于A组(P<0.05);两组不良反应发生率对比差异无统计学意义(P>0.05)。结论:应用安罗替尼于中晚期肝癌介入术后的治疗,可缓解病灶、控制病情的作用,安全可靠,值得临床推广应用。

Objective:To analyze the clinical efficacy of Amlotinib after interventional treatment of advanced liver cancer.Method:A total of 60 patients with advanced liver cancer treated from January 2014 to January 2016 in our hospital were selected and divided into two groups according to random number table method,30 cases in each group.Group A was treated with hepatocellular carcinoma interventional therapy,and group B was treated with interventional therapy combined with Amlotinib.The indexes of liver function,the occurrence of adverse reactions,tumor control rate and the total effective rate before and after treatment were compared and observed between the two groups.Result:There were no significant differences in the level of AST and ALT of between the two groups (P>0.05).The tumor control rate and total effective rate in group B were higher than those in group A (P<0.05).The average survival cycle of group B was longer than that of group A (P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05).Conclusion:The application of Amlotinib in the treatment of advanced liver cancer after interventional surgery can relieve the lesions and control the disease,which is safe and reliable and worthy of clinical application.